ReviewMethamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Section snippets
The methamphetamine problem
Methamphetamine (MA) is a psychostimulant drug with significant abuse potential and neurotoxic effects that acts principally to cause the release of central and peripheral monoamines (Gold et al., 2009). The compound was first synthesized from ephedrine in 1893 by the Japanese scientist Nagai Nagayoshi, 6 years after the discovery of amphetamine (see Fig. 1). In 1919, Akira Ogata synthesized crystallized MA by reducing ephedrine using red phosphorous and iodine, providing the basis for
Mechanism of action of amphetamines
Methamphetamine is a potent psychostimulant that acts primarily to cause the release of the monoamines dopamine, serotonin and norepinephrine. Norepinephrine is released most efficiently, followed by dopamine and then serotonin (Rothman et al., 2001). The mechanism of action of MA and other amphetamines has been described in extensive detail in several excellent reviews (Weiland-Fiedler et al., 2004, Fleckenstein et al., 2007, Sulzer et al., 2005). However, it is informative to summarize
Physiological and psychological effects of methamphetamine
Methamphetamine is a potent psychomotor stimulant drug with strong physiological effects on peripheral and central systems, resulting in both physical and psychological alterations. The drug can be consumed in multiple different ways and the physiological effects of MA occur rapidly and last for hours (see Table 1 for pharmacokinetics of MA). Through its action on epinephrine and norepinephrine release by the medulla of the adrenal glands, MA simulates the activation of the sympathetic division
Neurotoxicity of methamphetamine
In the animal literature, numerous studies have documented dopamine neuron terminal damage or loss after MA exposure (Krasnova and Cadet, 2009, Ricaurte et al., 1984), while a significantly smaller proportion of studies have reported actual cell loss via apoptosis in the striatum (Commins and Seiden, 1986, Tulloch et al., 2011). The relationship between these two different types of neurotoxicity remains unclear, particularly as the phenotype of apoptotic cells require further study. As of yet,
Neurocognitive effects of methamphetamine
Cognitive deficits have been widely described in “chronic” MA users. Chronicity is variably defined in the literature, with a meta-analysis indicating that 10 years of MA use is the approximate average for subjects enrolled in the various studies of MA use and cognitive sequelae (Scott et al., 2007). Chronic exposure to MA can result in severe neuropsychological deficits (summarized in Nordahl et al., 2003, Scott et al., 2007). Cognitive impairment is a serious concern for MA users, as it has
Treatment of methamphetamine-related disorders
Different pharmacological approaches have been tried in the treatment of MA addiction. The most common classes of drugs include antidepressants, antipsychotics and substitution/replacement therapies (Rose and Grant, 2008). Indirect evidence supports a rationale for the use of antidepressants – particularly those with a serotonergic mechanism of action, based on efficacy in preclinical models, clinical efficacy in treating compulsive behavior, and potential for ameliorating the affective
Conclusion
Methamphetamine is a highly addictive psychostimulant drug that acts on the central nervous system through multiple physiological pathways to cause the release of central and peripheral monoamine neurotransmitters. Recreational use of MA remains high in many parts of the United States and Canada and is increasing in other parts of the world. The highly addictive properties of this drug result in widespread psychosocial issues that include medical and legal problems, at-risk behaviors, and
Role of funding source
Funding for this study was provided by NSERC Grant 356069-09 to Dr. Barr. NSERC had no further role in the writing of the review; or in the decision to submit the paper for publication.
Contributors
All authors participated in the writing and revision of the review.
Conflict of interest
There are no conflicts of interest for any authors with respect to the present review.
Acknowledgments
W.J.P. is a Clinician Investigator Program research fellow. The editorial assistance of Heidi Boyda is appreciated.
References (211)
- et al.
Unique responses of limbic met-enkephalin systems to low and high doses of methamphetamine
Brain Res.
(2001) - et al.
Higher diffusion in striatum and lower fractional anisotropy in white matter of methamphetamine users
Psychiatry Res.
(2009) - et al.
The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats
Neurotoxicology
(2004) - et al.
Psychostimulant withdrawal as an inducing condition in animal models of depression
Neurosci. Biobehav. Rev.
(2005) - et al.
Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of d-amphetamine
Pharmacol. Biochem. Behav.
(2002) - et al.
Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat
Pharmacol. Biochem. Behav.
(1999) - et al.
Chronic corticosterone enhances the rewarding effect of hypothalamic self-stimulation in rats
Brain Res.
(2000) - et al.
Exposure to repeated, intermittent d-amphetamine induces sensitization of HPA axis to a subsequent stressor
Neuropsychopharmacology
(2002) - et al.
A ‘crash’ course on psychostimulant withdrawal as a model of depression
Trends Pharmacol. Sci.
(2002) - et al.
Preclinical models of antipsychotic drug-induced metabolic side effects
Trends Pharmacol. Sci.
(2010)
Molecular bases of methamphetamine-induced neurodegeneration
Int. Rev. Neurobiol.
Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs
Drug Alcohol Depend.
Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat
Eur. J. Pharmacol.
Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users
Psychiatry Res.
Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response
Biol. Psychiatry
Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy
Brain Res.
Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults
Drug Alcohol Depend.
Alpha-methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex
Brain Res.
Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry
Neuroimage
The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers
Pharmacol. Biochem. Behav.
Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding
Drug Alcohol Depend.
Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications
Neuropharmacology
Amphetamine releases dopamine from synaptic vesicles by dual mechanisms
Neurosci. Lett.
Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport
Neuron
Brain levels of neuropeptides in human chronic methamphetamine users
Neuropharmacology
Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates
Biol. Psychiatry
Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period
J. Subst. Abuse Treat.
Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure
Drug Alcohol Depend.
Mirtazapine alters cue-associated methamphetamine seeking in rats
Biol. Psychiatry
Extended access to methamphetamine self-administration affects sensorimotor gating in rats
Behav. Brain Res.
The methamphetamine experience: a NIDA partnership
Neuropharmacology
Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment
Eur. J. Pharmacol.
Response of limbic neurotensin systems to methamphetamine self-administration
Neuroscience
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
Drug Alcohol Depend.
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
Drug Alcohol Depend.
Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT
Prog. Neuropsychopharmacol. Biol. Psychiatry
Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine
Eur. J. Pharmacol.
Reduced corpus callosum white matter microstructural integrity revealed by diffusion tensor eigenvalues in abstinent methamphetamine addicts
Neurotoxicology
Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum
J. Neurochem.
Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix
J. Neurochem.
History of the methamphetamine problem
J. Psychoactive Drugs
Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement
Psychopharmacology (Berl.)
Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats
Psychopharmacology (Berl.)
The need for speed: an update on methamphetamine addiction
J. Psychiatry Neurosci.
Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity
Neuropsychopharmacology
Abuse of amphetamines and structural abnormalities in the brain
Ann. N. Y. Acad. Sci.
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?
J. Neurosci.
Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction
Synapse
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants
J. Pharmacol. Exp. Ther.
Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats
Psychopharmacology (Berl.)
Cited by (328)
Altered spontaneous neurological activity in methamphetamine use disorders and its association with cognitive function
2024, Asian Journal of PsychiatryCrystal methamphetamine and its effects on mental and oral health: A narrative review
2024, Saudi Dental JournalMovement disorders associated with substance use in adults living in precarious housing or homelessness
2023, Progress in Neuro-Psychopharmacology and Biological Psychiatry